Kong Jun

8PUBLICATIONS
11CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursHaematologyCancer therapy (excl. chemotherapy and radiation therapy)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 16, 2025
Upadacitinib, a selective JAK1 inhibitor, for the treatment of steroid refractory chronic graft-versus-host disease: A multicentre real-world study.

Liting Niu, Minli Hu, Yi Xia

|Sep 28, 2024
Mega-dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study.

Meng Lv, Chen-Hua Yan, Rui Ma

|Aug 05, 2024
Clinical features and prognostic model for viral encephalitis after allogeneic haematopoietic stem cell transplantation.

Jin Wu, Yu-Chen He, Qiu-Sha Huang

|Jul 19, 2021
Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.

Jun Kong, Ya-Zhen Qin, Xiao-Su Zhao

|Jul 01, 2021
Interferon-α as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia.

Hao Jiang, Xiao-Hong Liu, Jun Kong

|Feb 22, 2021
Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors.

Kong Jun, Qin Ya-Zhen, Zhao Xiao-Su

Pageof 2

Frequent Collaborators

3 joint publications

Xiao-Jun Huang

2 joint publications

Lan-Ping Xu

2 joint publications

Yu Wang

2 joint publications

Meng Lv